← All trials
NCT02977715
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 23, 2017
- Primary completion
- Feb 1, 2020
- Completion date
- Feb 1, 2020
- First posted
- —
- Last posted
- —
- Enrollment
- 1000
- Arms / groups
- 1 / —
- Source
- AACT · pre-existing
Sponsors
- Centers for Disease Control and Prevention (CDC)Lead sponsor
- Bavarian NordicCollaborator
- Government of the Democratic Republic of the CongoCollaborator
- University of KinshasaCollaborator
- Centers for Disease Control and Prevention (CDC)Overall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.